RxSight, Inc. (NASDAQ:RXST) Insider Sells $224,250.00 in Stock

Posted by Tech Dows on Nov 21st, 2024

RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 4,875 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $46.00, for a total transaction of $224,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,943,316. This represents a 10.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total value of $61,352.90.
On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total transaction of $161,180.55.
On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.

RxSight Stock Performance

RxSight stock opened at $44.81 on Thursday. RxSight, Inc. has a 12 month low of $27.51 and a 12 month high of $66.54. The stock’s 50-day moving average is $49.78 and its 200-day moving average is $52.98.

Wall Street Analyst Weigh In

A number of brokerages have commented on RXST. Wells Fargo & Company lowered their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Oppenheimer decreased their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Stifel Nicolaus decreased their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight presently has a consensus rating of “Buy” and a consensus price target of $61.63.

Check Out Our Latest Analysis on RXST

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Brown Capital Management LLC purchased a new stake in shares of RxSight in the third quarter worth about $26,813,000. Point72 Asset Management L.P. lifted its position in RxSight by 610.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after acquiring an additional 384,041 shares in the last quarter. Marshall Wace LLP purchased a new position in RxSight in the 2nd quarter worth approximately $19,512,000. Driehaus Capital Management LLC raised its stake in shares of RxSight by 74.9% during the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the period. Finally, Baillie Gifford & Co. lifted its position in shares of RxSight by 438.8% during the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after purchasing an additional 291,733 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

About RxSight

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.